Table 2B

Concomitant LLT at baseline and at end of follow-up (FAS; n=200)*

LLT at baselineLLT at 12 weeks
N (%)N (%)
Alirocumab*200 (100.0)198 (100.0)
Atorvastatin*81 (40.5)85 (42.9)
Simvastatin*14 (7.0)20 (10.1)
Rosuvastatin*24 (12.0)32 (16.2)
Fluvastatin*5 (2.5)11 (5.5)
Pravastatin*4 (2.0)9 (4.5)
Ezetimibe*90 (45.0)99 (50.0)
Other†10 (5.0)17 (8.6)
None0 (0.0)0 (0.0)
Any alirocumab combination157 (78.5)162 (81.8)
Any statin + Ezetimibe65 (32.5)74 (37.4)
Any other combination0 (0.0)0 (0.0)
  • *Alone or in combination.

  • †Including colesevelam hydrochloride.

  • FAS, full analysis set; LDL-C, low density lipoprotein cholesterol; LLT, lipid-lowering therapy.